title: Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives.
abstract: Primary systemic therapy represents the standard of care for locally advanced breast cancer and has becoming an attractive alternative in earlier stages. A part from the proven advantage of increasing the rate of breast conservative surgery, the up front use of systemic therapy can allow for an in vivo test of treatment sensitivity, and response to primary treatment discriminates patients at different prognosis. This review will summarize the more relevant data on the preoperative treatment with chemotherapy, hormonal therapy and targeted agents.
authors.affiliation: Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy. guarneri.valentina@unimore.it
authors.forename: Valentina
authors.initials: V
authors.lastname: Guarneri
authors.forename: Antonio
authors.initials: A
authors.lastname: Frassoldati
authors.forename: Simona
authors.initials: S
authors.lastname: Giovannelli
authors.forename: Francesca
authors.initials: F
authors.lastname: Borghi
authors.forename: PierFranco
authors.initials: P
authors.lastname: Conte
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006801:Humans; D016032:Randomized Controlled Trials as Topic
chemical_list: D000970:Antineoplastic Agents